Allison is Associate Editorial Director for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®. She joined AJMC® in 2017. She produces and oversees written, video, and podcast content across several disease states and issues surrounding value-based care and health policy.
She has an MPA from New York University. You can connect with Allison on LinkedIn.
Research Lends More Support for Mediterranean Diet to Protect Brain Health
April 21st 2022Adherence to a Mediterranean diet, which modulates gut microbiota, offers some protection against Alzheimer disease, but results of the review indicated more research is needed to understand the effect on Parkinson disease.
Study Examines Impact of Biologics for Asthma on HCRU
April 21st 2022The research, conducted in Germany, found that biologic treatment for asthma resulted in reduced health care resource utilization (HCRU), as seen in fewer hospitalizations and oral corticosteroid prescriptions as well as less sick leave.
In Adults With EoE, Dilation May Mask Underlying Inflammation
April 15th 2022The study was conducted because information on the relationship between eosinophilic esophagitis (EOE) symptoms and biologic findings are limited, so researchers looked at the long-term effects of esophageal dilation, including patient-reported outcome (PRO) measures.
ICER Examines Possible Policies Aimed at Sustaining Future Rare Disease Drug Development
April 14th 2022The Institute for Clinical and Economic Review (ICER) and researchers at NORC at the University of Chicago released a white paper that looks at the future of affordability and sustainability of drug development for rare disease through the lens of 4 policy proposals.
Incremental Steps Helpful but Not Enough to End Underinsurance Issue, Panelists Say
April 7th 2022Without addressing rising costs, the problem of underinsurance in health care coverage will remain, said panelists at the 2022 V-BID Summit, discussing some of the smaller steps that are being proposed or are already in place to try to ease the financial burden.
Increasing Health Equity to Reduce Disparities in Value-Based Care
April 7th 2022At the 2022 V-BID Summit, hosted by the Center for Value-Based Insurance Design at the University of Michigan, representatives of CMS and the Commonwealth Fund gave an update on the efforts to monitor, evaluate, and improve health equity in the United States.
Examining Adjuvant Therapies in PD When Levodopa Wanes
March 19th 2022A randomized clinical trial examined patient quality of life in Parkinson disease (PD) when adding different adjuvant therapies to levodopa to help control dyskinesia and a flaring of symptoms during OFF periods to see if one drug class had any benefit over another.
Treadmill Training Beneficial for Patients With Parkinson Disease
March 18th 2022This review sought to give more information about the types of treadmill training that might be beneficial for patients with Parkinson disease and other neurological disorders engaged in physical rehabilitation programs.
Asthma Researchers Examine Racial, Ethnic Experiences, Representation
March 5th 2022Although asthma disproportionately affects Blacks and Hispanics in the United States, they are more likely to be dissatisfied with their care teams as well as underrepresented in research, according to abstracts at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.
Looking Beyond COVID-19, US Health Officials Outline Next Steps to Fight Disease
March 2nd 2022From one-stop testing and treatment sites to boosting research and surveillance, Biden administration health officials expanded on the COVID-19 plan the president announced in his State of the Union address Tuesday night, but the plan will require additional funding from Congress.
Second Phase 3 Trial Shows Dupilumab Improves EoE in Patients 12 and Older
February 26th 2022During the annual meeting of the American Academy of Allergy, Asthma and Immunology, presenters said findings from a second phase 3 trial of dupilumab for eosinophilic esophagitis (EoE) continued to show the biologic improved symptoms in adults and adolescents.